Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$309.70 -0.8%	$277.63	$205.87 ▼ $317.54	$40.38B	0.22	925,992 shs	1.34 million shs
GSK GSK	$37.99 -1.7%	$38.58	$31.72 ▼ $44.67	$77.79B	0.52	4.92 million shs	8.25 million shs
VRTX Vertex Pharmaceuticals	$440.87 -1.7%	$459.22	$377.85 ▼ $519.88	$113.22B	0.42	1.41 million shs	2.17 million shs
ZTS Zoetis	$157.26 +1.4%	$159.58	$139.70 ▼ $200.33	$70.01B	0.94	2.54 million shs	3.30 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+0.56%	+6.81%	+6.54%	+86.90%
GSK GSK	0.00%	-6.92%	-1.81%	-1.53%	-6.14%
VRTX Vertex Pharmaceuticals	0.00%	-3.20%	+1.12%	-13.85%	-5.94%
ZTS Zoetis	0.00%	-4.27%	-3.47%	-3.65%	-8.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.0386 of 5 stars	2.4	5.0	0.0	4.3	2.0	2.5	0.6
GSK GSK	2.3277 of 5 stars	1.1	4.0	2.5	0.0	2.7	0.0	2.5
VRTX Vertex Pharmaceuticals	4.6188 of 5 stars	3.3	5.0	0.0	3.3	3.5	2.5	1.3
ZTS Zoetis	4.6074 of 5 stars	3.5	3.0	4.2	0.4	3.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	3.19% Upside
GSK GSK	2.27	Hold	$37.38	-1.63% Downside
VRTX Vertex Pharmaceuticals	2.55	Moderate Buy	$513.14	16.39% Upside
ZTS Zoetis	3.00	Buy	$212.13	34.89% Upside

Current Analyst Ratings Breakdown

Latest VRTX, ALNY, ZTS, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$464.00 ➝ $460.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/17/2025	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$423.00 ➝ $420.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/23/2025	VRTX Vertex Pharmaceuticals	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	VRTX Vertex Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
5/6/2025	VRTX Vertex Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	17.96	N/A	N/A	$0.52 per share	595.58
GSK GSK	$40.10B	1.94	$5.57 per share	6.82	$8.07 per share	4.71
VRTX Vertex Pharmaceuticals	$11.02B	10.27	N/A	N/A	$63.72 per share	6.92
ZTS Zoetis	$9.26B	7.56	$7.07 per share	22.23	$10.57 per share	14.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	347.98	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.58	8.17	1.33	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	25.18	N/A	-8.91%	-3.36%	-2.42%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.23	23.30	2.61	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest VRTX, ALNY, ZTS, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.69	4.45%	N/A	87.11%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.27%	N/A	35.91%	14 Years

Latest VRTX, ALNY, ZTS, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
GSK GSK	1.21	0.87	0.58
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
GSK GSK	15.74%
VRTX Vertex Pharmaceuticals	90.96%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
GSK GSK	10.00%
VRTX Vertex Pharmaceuticals	0.20%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

VRTX, ALNY, ZTS, and GSK Headlines

Recent News About These Companies

Oppenheimer Asset Management Inc. Acquires 43,325 Shares of Zoetis Inc. (NYSE:ZTS)

June 23 at 7:19 AM | marketbeat.com

2 S&P 500 Stocks on Our Watchlist and 1 to Think Twice About

June 23 at 6:59 AM | finance.yahoo.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Sawgrass Asset Management LLC

June 23 at 6:15 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

June 23 at 5:05 AM | marketbeat.com

Cullinan Associates Inc. Sells 2,400 Shares of Zoetis Inc. (NYSE:ZTS)

June 23 at 4:38 AM | marketbeat.com

Intact Investment Management Inc. Boosts Stake in Zoetis Inc. (NYSE:ZTS)

June 23 at 4:37 AM | marketbeat.com

76,510 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Vantage Investment Partners LLC

June 22 at 6:09 AM | marketbeat.com

Harvey Investment Co. LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 22 at 5:59 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 157,309 Shares of Zoetis Inc. (NYSE:ZTS)

June 22 at 3:21 AM | marketbeat.com

Fishman Jay A Ltd. MI Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 21 at 7:31 AM | marketbeat.com

Union Savings Bank Lowers Position in Zoetis Inc. (NYSE:ZTS)

June 21 at 7:31 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Holdings Raised by Nilsine Partners LLC

June 21 at 7:09 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Appleton Partners Inc. MA

June 21 at 6:16 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Cabot Wealth Management Inc.

June 21 at 5:59 AM | marketbeat.com

Dupont Capital Management Corp Acquires 27,864 Shares of Zoetis Inc. (NYSE:ZTS)

June 21 at 5:32 AM | marketbeat.com

Covea Finance Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

June 21 at 5:22 AM | marketbeat.com

Envestnet Portfolio Solutions Inc. Has $6.77 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

June 21 at 4:23 AM | marketbeat.com

Boston Trust Walden Corp Buys 7,542 Shares of Zoetis Inc. (NYSE:ZTS)

June 21 at 4:23 AM | marketbeat.com

Unusually Active Put Options Signal Long Straddle Opportunity After Zoetis Downgrade

June 20 at 8:52 PM | finance.yahoo.com

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

June 20 at 12:41 PM | zacks.com

S&P Futures Slip as Israel-Iran Conflict Remains in Focus

June 20 at 8:47 AM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX, ALNY, ZTS, and GSK Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$309.70 -2.62 (-0.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$315.00 +5.31 (+1.71%)

As of 06/20/2025 07:57 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

GSK NYSE:GSK

$37.99 -0.65 (-1.67%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$37.76 -0.23 (-0.62%)

As of 07:24 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Vertex Pharmaceuticals NASDAQ:VRTX

$440.87 -7.53 (-1.68%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$442.26 +1.39 (+0.32%)

As of 07:08 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zoetis NYSE:ZTS

$157.26 +2.20 (+1.42%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$156.58 -0.67 (-0.43%)

As of 07:14 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time